The following are studies that used ADDRESS-2 to find and contact candidates:
Research study for people with Type 1 Diabetes: EXALT
No longer recruiting
Summary
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes. The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
ADDRESS C-Peptide
No longer recruiting
Summary
Observational study to find out how much insulin people with type 1 diabetes can make themselves within the first year of having diagnosis and how C-peptide varies with time since diagnosis in children and adults.
EXTOD Education
No longer recruiting
Summary
We (the EXTOD Education Team) want to find the best way to support adults with Type 1 diabetes to manage their glucose during and after exercise, so that they can exercise safely. Our research study, the ‘EXTOD education’ study, has developed a NEW intervention (an education programme) to assist in achieving this goal.
We are inviting people with Type 1 diabetes to participate in a Pilot Randomised Controlled Trial, involving 8 visits over an 8 month period, to test the new education programme.
The Effect of Abatacept on the Immune System in Type 1 Diabetes
No longer recruiting
Summary
This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells. Participants will be given the drug Abatacept for 6 months, in addition to their regular diabetes medication. They will have blood tests before, during and after treatment so that their immune cells can be analysed.
Exploration of the peripheral immune system in subjects with New Onset T1 Diabetes (NOT1D)
No longer recruiting
Summary
This study aims to gain a better understanding of the processes that may lead to the immune system’s destruction of insulin producing beta cells, which help to control blood sugar levels. This study involves taking a biopsy (a sample of tissue taken from the body in order to examine it more closely) from a lymph node found in the groin area.
The effect of anti-IL-21 and liraglutide in newly diagnosed type 1 diabetes
No longer recruiting
Summary
This study will investigate if a new drug called NNC01140006 (Anti-IL-21) when given together with another drug marketed for type 2 diabetes called liraglutide (Victoza®) can preserve the beta cells in subjects diagnosed with type 1 diabetes.
MultiPepT1De
No longer recruiting
Summary
Trial of a potential vaccine for type 1 diabetes for adults aged 18-45 years, within 4 years of diagnosis.
www.multipeptide.co.uk
Aim
To investigate the possibility of slowing the progression of type 1 diabetes using a “vaccine”. The vaccine is made from fragments of the protein molecules found in the beta cells of the pancreas, called peptides. The aim is to re-train the immune system so that it stops recognising beta cells as a target to attack. The current study is testing the safety of the vaccine as well as its effects on the immune system.
Who is running this study?
This study is academically led and is being run by Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The Chief Investigator is Dr Jake Powrie.
It is funded by a grant from UCB Pharma.
Adaptive study of IL-2 dose frequency on regulatory T Cells in Type 1 Diabetes (DILfrequency)
No longer recruiting
Summary
Trial for people aged 18-70 within 5 years of diagnosis, investigating a new medication called aldersleukin (interleukin-2) for use in type 1 diabetes.
www.clinical-trials-type1-diabetes.com
Aim
The research team are investigating whether this medication can halt the damage to the pancreas of people recently diagnosed with type 1 diabetes and if so, how often the drug is required for the best results.
Who is running this study?
This study is being run by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The Chief Investigator was Dr Frank Waldron-Lynch.
It is funded by the Sir Jules Thorn Charitable Trust.
The effect of lixisenatide in type 1 diabetes study (Lixi study)
No longer recruiting
Summary
Study using a glucose-lowering drug called lixisenatide that has been licenced in Europe for use in type 2 diabetes. This study is looking to see how the same drug affects people with type 1 diabetes and is for adults aged 18-70 years with a diabetes duration of 12 months or more.
Aim
To find out whether a daily injection of lixisenatide, along with prescribed insulin treatment, can improve blood sugar control in people with type 1 diabetes. Also to find out if there is a difference between participants with low insulin production from the pancreas and those who do not produce insulin from the pancreas.
Who is running this study?
This is an academic-led study being run by a team within the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) and funded by an educational grant from Sanofi. The Chief Investigator is Professor Stephen Gough, Consultant Physician.